Skip to Main Content
Table 1—

Screening characteristics

n 17 
Sex (M/F) 14/3 
Ethnicity (Caucasian/African-American) 9/8 
Age (years) 56 ± 3 (37–70) 
Duration of type 2 diabetes (years) 7 ± (1–16) 
Weight (kg) 102.3 ± 5.2 (69.5–151.5) 
Height (cm) 175 ± 2 (157–196) 
BMI (kg/m233.1 ± 1.4 (25.1–44.9) 
HbA1c (%) 8.8 ± 0.4 (6.1–11.8) 
Microalbumin (μg/ml) 83 ± 17 (22–311)* 
Oral antidiabetic agent/diet (yes/no) 16/1 
 Sulfonylureas 
 Biguanides 
 Biguanides + sulfonylureas 
ACE inhibitor (yes/no) 8/9 
 ACE-1 
 ARB 
 ARB or ACE-1 + β-blocker 
Systolic blood pressure (mmHg) 151 ± 4 (111–177)* 
Diastolic blood pressure (mmHg) 85 ± 2 (73–94)* 
Smoke (yes/no) 3/14 
Lipid medications (yes/no) 4/13 
 Gemfibrazole 
 Gemfibrazole + niacin 
 HMG-CoA reductase inhibitors 
n 17 
Sex (M/F) 14/3 
Ethnicity (Caucasian/African-American) 9/8 
Age (years) 56 ± 3 (37–70) 
Duration of type 2 diabetes (years) 7 ± (1–16) 
Weight (kg) 102.3 ± 5.2 (69.5–151.5) 
Height (cm) 175 ± 2 (157–196) 
BMI (kg/m233.1 ± 1.4 (25.1–44.9) 
HbA1c (%) 8.8 ± 0.4 (6.1–11.8) 
Microalbumin (μg/ml) 83 ± 17 (22–311)* 
Oral antidiabetic agent/diet (yes/no) 16/1 
 Sulfonylureas 
 Biguanides 
 Biguanides + sulfonylureas 
ACE inhibitor (yes/no) 8/9 
 ACE-1 
 ARB 
 ARB or ACE-1 + β-blocker 
Systolic blood pressure (mmHg) 151 ± 4 (111–177)* 
Diastolic blood pressure (mmHg) 85 ± 2 (73–94)* 
Smoke (yes/no) 3/14 
Lipid medications (yes/no) 4/13 
 Gemfibrazole 
 Gemfibrazole + niacin 
 HMG-CoA reductase inhibitors 

Data are means ± SE (range) or n.

*

To meet recruitment goals, microalbumin and blood pressure exclusion criteria were broadened slightly. HMG, hydroxymethylglutaryl.

Close Modal

or Create an Account

Close Modal
Close Modal